• The Korean Journal of Nuclear Medicine Technology
• /
• v.12 no.1
• /
• pp.126-129
• /
• 2008

목적: 방사성옥소 치료 환자들은 주의 사항이나 식이요법 등을 지키는 것에 대한 어려움과 3~4일간의 격리 치료기간 동안의 막연한 불안감을 느끼는 등의 심리적, 신체적 부담감을 가지고 있다. 본 과에서는 방사성옥소 치료의 예약과 치료병실에 대한 표준지침서를 개발하여 환자들에게는 정확하고 쉬운 정보를 제공하여 막연한 불안감을 해소하고 치료 업무에 종사하는 종사자들에게는 통일된 정보를 제공하여 업무효율을 향상시키는 효과와 치료 병실의 환경개선을 통한 환자의 심리적 안정감을 찾는데 주력하고자 본 연구를 시작하였다. 대상 및 방법: 2006년 9월부터 2007년 2월까지 치료병실에 입원한 환자를 대상으로 치료환자의 치료 일정, 주의사항, 저옥소 식단과 치료병실의 표준 진료 지침서를 개발하고 치료 병동의 간호사와 협력하여 치료병실의 환경을 개선하여 환자에게 적용하였다. 결과: 방사성옥소 치료의 특성상 환자는 치료가 결정되는 순간부터 치료과정에 대한 이해도 부족과 치료병실 생활에 대한 불안감을 느끼게 되므로 치료 시 사용되는 일정 및 주의사항, 저옥소 식단의 표준지침서를 개발하여 환자 치료병실 개선과 치료병실에서의 표준지침서를 개발하고 사용하였다. 결론: 치료에 따른 진료지침서와 병실 환경을 개선 후 치료에 대한 환자의 이해도 및 치료병실에서의 생활이 예전과 비교해서 많이 향상 되었고 치료의 과정을 설명하는 예약 시에도 많은 도움이 되고 있다. 이러한 치료과정의 규격화 하는 작업들은 본원뿐 아니라 치료병실이 있는 병원의 치료환경을 개선하는데 도움이 될 것이라고 사료된다.

• Journal of radiological science and technology
• /
• v.30 no.4
• /
• pp.435-442
• /
• 2007

The number of thyroid diseases treated with radioiodine(I-131) is increasing steadily. The sharp increase in patients who require high dose radioiodine therapy greatly increased the need for new therapy rooms. Accordingly, interest in radiation exposure is rising as well, and is a major psychological stress factor for the patient and those who come in close contact with the patient. This study aimed to minimize the radiation exposure on discharge. Based on various previous reports, the decision for discharge should be individualized depending on many factors related to the patient's living or working environment. Educating patients repeatedly on the importance of sufficient oral hydration, while the adequate amount was relative to the patient's individual condition, greatly lowered the detected radiation measurement within the same admission period. In some cases, the period of admission could be abbreviated.

• The Korean Journal of Nuclear Medicine
• /
• v.30 no.1
• /
• pp.77-85
• /
• 1996

Radioiodine($^{131}I$) has been used for the treatment of Graves' hyperthyroidism since the late 1940's and is now generally regarded as the treatment of choice for Graves' hyperthyroidism who does not remit following a course of antithyroid drugs. But for the dose given, several different protocols have been described by different centers, each attempting to reduce the incidence of long-term hypothyroidism while maintaining an acceptable rate control of Graves' hyperthyroidism. Our goals were to evaluate effective half-life and predict absorbed dose in Graves' hyperthyroidism patients, therefore, to calculate and readminister radioiodine activity needed to achieve aimed radiation dose. Our data showed that the mean effective $^{131}I$ half-life for Graves' disease is 5.3 days(S.D=0.88) and mean biologic half-life is 21 days, range 9.5-67.2 days. The mean admininistered activity and the mean values of absorbed doses were 532 MBq(S.D.=254), 112 Gy (S.D.=50.9), respectively. The mean activity needed to achieve aimed radiation dose were 51MBq and marked differences of $^{131}I$ thyroidal uptake between tracer and therapy ocurred in our study. We are sure that the dose calculation method that uses 5 days thyroidal $^{131}I$ uptake measurements after tracer and therapy dose, provides sufficient data about the effective half-life and absorbed dose of $^{131}I$ in the thyroid and predict the effectiveness of $^{131}I$ treatment in Graves' hyperthyroidism.

• 대한방사선방어학회:학술대회논문집
• /
• 2009.04a
• /
• pp.160-161
• /
• 2009

• The Korean Journal of Nuclear Medicine Technology
• /
• v.12 no.1
• /
• pp.130-136
• /
• 2008

목적: 방사성옥소 치료를 받는 많은 환자들이 장기간의 전처치와 격리 입원 동안에 신체적 불편함을 호소하므로 이를 줄여주기 위하여 첫째, 방사성옥소 치료 전 환자들이 저옥소식을 잘 지킬 수 있도록 도움을 주며 둘째, 4일간의 격리입원기간 동안 심리적 어려움과 신체 적불편함을 줄여줌으로써 환자의 만족도를 향상시키는 효과를 기대하고자 본 연구를 하였다. 대상 및 방법: 1. 연구자들의 브레인스토밍을 통해 환자들의 불편함을 파악하였다. 2. 방사성옥소 치료를 위해 입원한 환자 36명에게 입원 기간 동안 느낀 점을 기록하게 하고 이를 조사하였다. 3. 환자 퇴원시에 치료과정에 대한 만족도 설문을 문제점 개선 전 33명, 개선 후 22명에게 조사하였다. 결과: 문제점과 개선안을 도출하였으며 가능한 범위 내에서 개선활동을 실시하였다. 그리고 만족도 설문을 조사하였으며 개선 전 후를 비교하였다. 문제점으로 1) 저옥소식: 맛이 없다, 반찬 가려 먹기가 어렵다. 2) 치료병실 생활: 속이 메스꺼워 음식 섭취가 곤란하다, 병실이 춥다. 3) 호르몬제 투여중지: 전신이 나른하다, 몸이 붓는다가 도출되었으며 이를 해결하기 위한 개선 활동은 1) 입원 전 예약 시에 음식조절(저옥소식)에 대한 설명을 자세히 하였다. 2) 타부서와의 협의-협조사항(치료병실의 청결유지와 쾌적한 병실을 만들기 위해 16층 병동과 협의, 저옥소식 영양상담을 치료 과정중에 넣기 위해 영양과와 협의, 온열매트리스 설치와 보온이불 구입을 위해 시설팀과 협의 등)을 해결하려 노력했다. 3) 전반적인 개선활동(방사성옥소를 차질없이 구입, 치료병실의 치료 전 후 방사능오염 방지, 환자의 심리적 불안감 해소 등)을 하였다. 환자의 만족도 설문에 대한 개선 활동 전 후 비교 결과에서 '치료과정 전체에 대해 힘들었다'는 개선 전 후에 각각 80.6%, 81.8%로 큰 차이가 없었다. 또한 문제점으로 도출된 '저옥소식이 힘들었다'는 개선 전 후에 각각 24.1%, 27.8%로 역시 큰 차이가 없었다. 그러나 '병실생활이 힘들었다'는 개선 전 후에 각각 48.3%, 72.2%로 큰 차이를 보였다. 그리고 '호르몬 투여중지로 인해 힘들었다'는 개선 전 후에 각각 27.6%, 0%로 큰 차이를 보였다. 고찰 및 결론: 환자들의 불편함을 줄여주기 위하여 연구자들의 개선활동이 있었고 그 중에서 입원병실의 생활환경이 특히 향상되었다. 그러나 결과에서 '병실생활이 힘들었다'에 대한 답의 비율은 오히려 더 높아졌다. 이는 '호르몬 투여 중지로 힘들었다'로 답하는 환자의 비율이 상대적으로 줄었기 때문에 높아진 것으로 생각되었다. 방사성옥소 치료로 인해 생길 수밖에 없는 신체적 반응 때문에 대부분의 환자들은 항상 힘들었다고 할 것이다. 만족도 개선 활동으로 환자의 힘든 치료과정을 완전히 해소시켜 줄 수는 없었으나 환자입장에서 생각할 수 있게 된 계기가 되었으며 좀 더 향상된 치료환경을 제공하는 기회가 되었다.

• Nuclear Medicine and Molecular Imaging
• /
• v.41 no.5
• /
• pp.343-349
• /
• 2007

Radioiodide transport has been extensively and successfully used in the evaluation and management of thyroid disease. The molecular characterization of the sodium/iodide symporter (NIS) and cloning of the NIS gene has led to the recent expansion of the use of radioiodide to cancers of the breast and other nonthyroidal tissues exogenously transduced with the NIS gene. More recently, discoveries regarding the functional analysis and regulatory processes of the NIS molecule are opening up exciting opportunities for new research and applications for NIS and radio iodide. The success of NIS based cancer therapy is dependent on achievement of maximal radioiodide transport sufficient to allow delivery of effective radiation doses. This in turn relies on high transcription rates of the NIS gene. However, newer discoveries indicate that nontranscriptional processes that regulate NIS trafficking to cell membrane are also critical determinants of radioiodide uptake. In this review, molecular mechanisms that underlie regulation of NIS transcription and stimuli that augment membrane trafficking and functional activation of NIS molecules will be discussed. A better understanding of how the expression and cell surface targeting of NIS proteins is controlled will hopefully aid in optimizing NIS gene based cancer treatment as well as NIS based reporter-gene imaging strategies.

• 대한핵의학회:학술대회논문집
• /
• 2003.11a
• /
• pp.10.2-10.2
• /
• 2003

• The Korean Journal of Nuclear Medicine
• /
• v.34 no.1
• /
• pp.22-29
• /
• 2000

Purpose: We compared the first postoperative diagnostic and post-therapy scans of patients who received therapeutic doses of I-131, to investigate the difference in clinical outcomes between patients with concordant findings of diagnostic and post-therapy scans and patients with discrepant (more lesions in post-therapy scan) findings. Materials and Methods: The first postoperative diagnostic and post-therapy radioiodine scans of one hundred forty three patients with well differentiated thyroid carcinoma were reviewed. Diagnostic scans were obtained following ingestion of 185 MBq of I-131 and post-therapy scans were obtained after therapeutic dose of $3.7{\sim}9.3$ GBq of I-131. Successful ablation was defined as no radioiodine uptake on diagnostic radioiodine scan and normal range of serum thyroglobulin level (<10 ng/ml) during serum TSH elevation. Results: Discrepant scan findings were noted in 25 (17.5%) patients. Twenty-two patients (15.4%) showed more lesions in post-therapy scan and 3 patients (2.1%) showed stunning effect. Nine (64.3%) of 14 patients with distant metastasis revealed metastatic lesion(s) only on post-therapy scan. Stunning effect was considered as sublethal damage in 1 patient and treatment by a diagnostic dose in 2 patients. Ablation was achieved in 52.4% (75/143) of all patients. Ablation rate and mean cumulative radioiodine dose were not different statistically between concordant and discrepant groups. Conclusion: There were 17.5% difference between diagnostic and post-therapy scan findings when using 185 MBq of I-131 as a diagnostic dose. However, 64.3% of distant metastases were revealed only on post-therapy scan. Ablation rate and mean cumulative radioiodine dose were not different statistically between concordant and discrepant groups. The stunning effect was considered as not only sublethal damage but also treatment by a small diagnostic dose of radioiodine.

• The Korean Journal of Nuclear Medicine
• /
• v.37 no.2
• /
• pp.110-119
• /
• 2003

Purpose: Radioiodine (I-131) therapy is an effective modality to reduce both recurrence and mortality rates in differentiated thyroid cancer. Whether higher doses shows higher therapeutic responses was still debatable. The purpose of this study was to validate curve-fitting (CF) method measuring maximum permissible dose (MPD) by a biological dosimetry using metaphase analysis of peripheral blood lymphocytes. Materials and Methods: Therapeutic effects of MPD was evaluated in 58 patients (49 females and 9 males, mean age $50{\pm}11$ years) of papillary thyroid cancer. Among them 43 patients were treated with ${\Leq}7.4GBq$, while 15 patients with ${\geq}9.25GBq$. The former was defined as low-dose group, and the latter high-dose group. Therapeutic response was defined as complete response when complete disappearance of lesions on follow-up I-131 scan and undetectable serum thyroglobulin levels were found. Statistical comparison between groups were done using chi-square test. P value less than 0.05 was regarded as statistically significant. Results: MPD measured by CF method using tracer and therapeutic doses were $13.3{\pm}1.9\;and\;13.8{\pm}2.1GBq$, respectively (p=0.20). They showed a significant correlation (r=0.8, p<0.0001). Exposed doses to blood measured by CF and biological methods were $1.54{\pm}0.03\;and\;1.78{\pm}0.03Gy$ (p=0.01). They also showed a significant correlation (r=0.86, p=0.01). High-dose group showed a significantly higher rate of complete response (12/15, 80%) as compared to the low-dose group (22/43, 51.2%) (p=0.05). While occurrence of side effects was not different between two groups (40% vs. 30.2%, p=0.46). Conclusion: Measurement of MPD using CF method is reliable, and the high-dose I-131 therapy using MPD gains significantly higher therapeutic effects as compared with low-dose therapy.

• Nuclear Medicine and Molecular Imaging
• /
• v.42 no.4
• /
• pp.301-306
• /
• 2008

Purpose: Recently, a number of patients needed total thyroidectomy and high dose radioiodine therapy (HD-RAI) get increased more. The aim of this study is to evaluate whether pathological staging (PS) and serum thyroglobulin (sTG) level could replace the diagnostic I-123 scan for the determination of therapeutic dose of HD-RAI in patients with differentiated thyroid cancer. Materials and Methods: Fifty eight patients (M:F=13;45, age $44.5{\pm}11.5\;yrs$) who underwent total thyroidectomy and central or regional lymph node dissection due to differentiated thyroid cancer were enrolled. Diagnostic scan of I-123 and sTG assay were also performed on off state of thyroid hormone. The therapeutic doses of I-131 (TD) were determined by the extent of uptakes on diagnostic I-123 scan as a gold standard. PS was graded by the criteria recommended in 6th edition of AJCC cancer staging manual except consideration of age. For comparison of the determination of therapeutic doses, PS and sTG were compared with the results of I-123 scan. Results: All patients were underwent HD-RAI. Among them, five patients (8.6%) were treated with 100 mCi of I-131, fourty three (74.1%) with 150 mCi, six (10.3%) with 180 mCi, three (5.2%) with 200 mCi, and one (1.7%) with 250 mCi, respectively. On the assessment of PS, average TDs were $154{\pm}25\;mCi$ in stage I (n=9), $175{\pm}50\;mCi$ in stage II (n=4), $149{\pm}21\;mCi$ in stage III (n=38), and $161{\pm}20\;mCi$ in stage IV (n=7). The statistical significance was not shown between PS and TD (p=0.169). Among fifty two patients who had available sTG, 25 patients (48.1%) having below 2 ng/mL of sTG were treated with $149{\pm}26\;mCi$ of I-131, 9 patients (17.3%) having $2{\leq}\;sTG\;<5\;ng/mL$ with $156{\pm}17\;mCi$, 5 patients (9.6%) having $5{\leq}\;sTG\;<10\;ng/mL$ with $156{\pm}13\;mCi$, 7 patients (13.5%) having $10{\leq}sTG\;<50\;ng/mL$ with $147{\pm}24\;mCi$, and 6 patients (11.5%) having above 50 ng/mL with $175{\pm}42\;mCi$. The statistical significance between sTG level and TD (p=0.252) was not shown. Conclusion: In conclusion, PS and sTG could not replace the determination of TD using I-123 scan for first HD-RAI in patients with differentiated thyroid cancer.